That all night be true but I'm pphm case, if big pharmaceutical believed the bavi story, they would be all over it. bavi would extend their products life cycle as it used in combo.
To address the need for an MRI contrast agent that demonstrates greater effectiveness and lower toxicity, Dr. Sitharaman developed a novel high-performance graphene-based contrast agent that may replace the gadolinium-based agent which is widely used by physicians today. “A graphene-based contrast agent can allow the same clinical MRI performance at substantially lower dosages,” said Dr. Sitharaman.
Then the below is a must read for those like myself who has and continue to undergo MRI's w/contrast.
SBU Researchers Develop Groundbreaking New Graphene-Based MRI Contrast Agent
June 7, 2012
Must be close on all fronts... including MRI
Convertible MRI contrast: Sensing the delivery and release of anti-glioma nano-drugs
Liang Zhang, Zhongwei Zhang, Ralph P. Mason, Jann N. Sarkaria & Dawen Zhao
Received 17 November 2014 Accepted 19 March 2015 Published 12 May 2015
Glioblastoma (GBM) is well known for its high resistance to chemotherapy, e.g., temozolomide (TMZ). Building upon the previously established phosphatidylserine (PS)-targeted nanoplatform that has excellent GBM-targeting specificity, we now demonstrate the effectiveness of the targeted nanoformulated ATO for treating TMZ-resistant GBM cells and the ability of the convertible Mn contrast as a surrogate revealing the delivery and release of ATO.
... ..
Affiliations
Radiology, UT Southwestern Medical Center, Dallas, TX Liang Zhang, Zhongwei Zhang, Ralph P. Mason & Dawen Zhao Radiation Oncology, Mayo Clinic, Rochester, MN Jann N. Sarkaria
Contributions
L.Z. and D.Z. designed research; L.Z., Z.Z. and D.Z. performed the research; L.Z., Z.Z. and D.Z. analyzed data; L.Z., R.M., J.S., and D.Z. wrote the paper. Competing financial interests
The authors declare no competing financial interests. Corresponding author